Isofol Medical AB Cash Flow Conversion Efficiency
Isofol Medical AB cash flow conversion efficiency. Based on the latest financial reports, Isofol Medical AB (ISOFOL) has a cash flow conversion efficiency ratio of -0.089x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-10.78 Million ≈ $-1.16 Million USD) by net assets (Skr120.62 Million ≈ $12.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Isofol Medical AB (2015–2025)
Cash flow conversion efficiency of Isofol Medical AB from 2015 to 2025. This chart illustrates how Isofol Medical AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Isofol Medical AB stock price today for real-time trading data and today's change.
Isofol Medical AB Cash Flow Conversion Ratio Explained
Isofol Medical AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Isofol Medical AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Isofol Medical AB ranked by their cash flow conversion efficiency. Also see market cap of Isofol Medical AB for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlockchAIn Digital Infrastructure, Inc
NYSE MKT:AIB
|
0.064x |
|
Lay Hong Bhd
KLSE:9385
|
0.018x |
|
BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877-
F:BLH
|
0.003x |
|
Grazziotin S.A
SA:CGRA3
|
0.028x |
|
DSR Corp
KO:155660
|
-0.010x |
|
PASSUS S.A. ZY-1
F:71X
|
0.559x |
|
Aarti Surfactants Limited
NSE:AARTISURF
|
0.091x |
|
HILONG HOLDING LTD HD-10
F:8HL
|
N/A |
Annual Cash Flow Conversion Efficiency for Isofol Medical AB (2015–2025)
The table below shows the annual cash flow conversion efficiency of Isofol Medical AB from 2015 to 2025. Review Isofol Medical AB free cash flow to debt ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr107.87 Million ≈ $11.61 Million |
Skr-51.94 Million ≈ $-5.59 Million |
-0.481x | +10.62% |
| 2024-12-31 | Skr77.94 Million ≈ $8.39 Million |
Skr-41.99 Million ≈ $-4.52 Million |
-0.539x | -24.51% |
| 2023-12-31 | Skr121.43 Million ≈ $13.07 Million |
Skr-52.54 Million ≈ $-5.65 Million |
-0.433x | +64.10% |
| 2022-12-31 | Skr158.48 Million ≈ $17.05 Million |
Skr-190.97 Million ≈ $-20.55 Million |
-1.205x | -103.52% |
| 2021-12-31 | Skr318.23 Million ≈ $34.25 Million |
Skr-188.43 Million ≈ $-20.28 Million |
-0.592x | +75.41% |
| 2020-12-31 | Skr66.57 Million ≈ $7.16 Million |
Skr-160.27 Million ≈ $-17.25 Million |
-2.408x | -71.58% |
| 2019-12-31 | Skr104.91 Million ≈ $11.29 Million |
Skr-147.21 Million ≈ $-15.84 Million |
-1.403x | -302.20% |
| 2018-12-31 | Skr265.01 Million ≈ $28.52 Million |
Skr-92.46 Million ≈ $-9.95 Million |
-0.349x | -93.21% |
| 2017-12-31 | Skr343.03 Million ≈ $36.92 Million |
Skr-61.94 Million ≈ $-6.67 Million |
-0.181x | +98.06% |
| 2016-12-31 | Skr6.10 Million ≈ $656.35K |
Skr-56.90 Million ≈ $-6.12 Million |
-9.330x | +66.45% |
| 2015-12-31 | Skr1.32 Million ≈ $142.27K |
Skr-36.77 Million ≈ $-3.96 Million |
-27.812x | -- |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. The company develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. Isofol Medical AB (publ) was incorporated in 2008 and is based in Gothenburg, Sweden.